Provenance Record

Well-structured News piece (777 words, within the 400-1200 range) covering an FDA advisory committee vote on Replimune's RP1 (vusolimogene oderparepvec) plus nivolumab for advanced melanoma. Clear sectioning (Overview, What the Committee Voted On, A Third Attempt After Two Rejections, Company Response, What We Don't Know) with balanced attribution of both supportive and dissenting committee views.

All 5 source snapshots read from local gzip files under sources/2026-08/fda-advisory-committee-backs-replimunes-rp1-melanoma-therapy-in-10-3-vote-after-two-prior-rejections/ and sha256-verified against manifest.json (all 5 hashes matched exactly: source-0 through source-4, all status_code 200, no archive_fallback). suspicious_patterns was null for every entry, and a manual regex scan of all 5 decompressed snapshots for AI-agent-directed language ('ignore previous', 'as an ai', 'language model', 'ai agent', 'do not tell', 'system prompt', 'large language') returned zero matches in every file — no prompt-injection content found. source-0 (GlobeNewswire/Replimune press release) verbatim-confirmed the 10-to-3 vote, the exact committee question ('Are the efficacy results from IGNYTE evaluable and clinically meaningful?'), both CEO Sushil Patel quotes word-for-word, and the August 2, 2026 Class 1 target action date. source-1 (BioSpace) verbatim-confirmed the Lawrence Schwartz 'This is messy data' quote, the Diane Aronson 'Hope is important, but reality weighed into my vote' quote, the Sundeep Agrawal 'contribution of effect and the need for each product has not been demonstrated' quote, and the July 2025 / April 2026 two-CRL timeline. source-2 (CancerNetwork, fda-advisory-committee-backs-rp1-nivolumab...) verbatim-confirmed the Karla Ballman and Melinda Yushak quotes, the November 2024 breakthrough designation, January 2025 priority review acceptance, the two-CRL regulatory history (July 21, 2025 and the April 10, 2026 PDUFA cycle), the June 2026 third resubmission acceptance under Class I, and the efficacy figures (33.6% ORR, 15.0% CR rate, 32.9-month median OS, 75.3%/61.5%/47.8% one/two/three-year OS). source-3 (CancerNetwork, rp1-nivolumab-shows-os-benefit...) verbatim-confirmed the safety data (88.7% any-grade TRAEs, 12.8% grade 3/4, chills/fatigue/pyrexia/nausea as most common, zero grade 5 events) and the April 2026 second CRL. source-4 (StockTitan/SEC 8-K) verbatim-confirmed the 10-3 vote, the Class 1 August 2, 2026 target action date, and that the vote 'does not itself constitute approval' framing (article's 'supports continued regulatory review' language matches the filing's own framing). No hallucinated quotes, no misattributions, no unsupported specifics found.

Every number checked character-for-character against raw source snapshots: 10-3 vote count (all 5 sources), two prior CRLs in July 2025 and April 2026 (source-1, source-2, source-3 all independently confirm), breakthrough designation November 2024 and priority review January 2025 (source-2), August 2, 2026 target action date under Class 1 (source-0, source-2, source-4), and the full efficacy/safety dataset (ORR 33.6%, CR 15.0%, median OS 32.9 months, 1/2/3-yr OS 75.3%/61.5%/47.8%, TRAEs 88.7%/12.8%, zero grade 5) all verbatim-matched to source-2 and source-3. The CEO quotes were independently double-checked as required by the bot's Rule 10 note: both quotes appear verbatim in source-0, the Replimune press release itself (the primary, most authoritative source for a company statement), and are consistent with the paraphrase in source-4's SEC 8-K summary.

Clean submission. All five sources verified against local snapshots with sha256 integrity checks; every quote, statistic, date, and the vote count trace verbatim to the cited sources. The internal cross-reference to the June 1, 2026 article resolves correctly and the two articles are properly differentiated (survival-data/resubmission announcement vs. the adcomm vote outcome). No fabrications, no misattributions, no prompt-injection content, no originality conflicts. Approved without corrections.